Reactive and Inactive Skin Decontamination Lotion SPE2DP23D0001

This is a Request for Information (RFI) only. This is not a Request for Proposal, Request for Quote, or Invitation for Bid. DLA Troop Support is seeking to identify possible sources that can manufacture the following: Reactive Skin Decontamination Lotion (RSDL), NSN 6505-01-507-5074 and Inactive Skin 5Decontamination Lotion (ISDL), NSN 6910-01-507-5141 RSDL shall made in accordance with MPID Number 3, dated 13 April 2022. RSDL is a topical lotion containing a free oxime dissolved in a maximum of polyethylene glycol monomethyl ether and water. It is intended to remove or neutralize chemical warfare (CW) agents, including many organophosphate-based pesticides and T-2 toxin from the skin. It will be pre-impregnated in a suitable sponge applicator pad. Each applicator pad shall be individually packaged in a heat sealed polyethylene-lined aluminum foil pouch. The foil pouch shall permit easy opening of the package when wearing CW protective clothing. Shall be cleared for use by the United States (U.S.) Food and Drug Administration (FDA) for application on unbroken skin of hands, face, neck, limbs and torso. ISDL shall be made in accordance with MPID Number 2, dated 13 April 2022. ISDL is a training lotion that imitates the properties of the decontamination lotion in all but active decontaminating ingredients. Annual estimated quantity is 13,434 packages (PG) for Skin Decontamination Lotion (RSDL) and 1,309 packages (PG) for Inactive Skin Decontamination Lotion (ISDL). Delivery shall occur 75 days after receipt of the order. Also, include surge and sustainment requirements for RSDL only. The annual estimated surge and sustainment requirement is 5,504 packages per month for 6 months; total delivered quantity in 6 months is 33,024 packages. Ordered quantities shall be delivered to military ordering activities or Defense Distribution Centers (DDC) located throughout the United States. If your firm can provide these items, please provide information with respect to the following: 1. Place of Manufacture 2. Estimated Annual Capacity 3. FDA registration information 4. Product Name and description including description of any special features 5. Current unit sale price 6. Estimated inventory level and storage requirements 7. Delivery days for each item 8. Capacity for surge and sustainment requirements *** New Products Under Development *** For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture lotions described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protection under the conditions of the Protect Critical infrastructure information (PCII) Program outlined in the Critical Infrastructure Information Act 2002. Your Response to this RFI may be submitted electronically in Word or pdf format and emailed to the Acquisition Specialist Damaris Masip (damaris.figueroa@dla.mil) and/or Contracting Officer Jessica De La Hoz (jessica.delahoz@dla.mil) on or before November 6, 2025.